help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on September 8, 2005, doi:10.1164/rccm.200504-613PP
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200504-613PPv1
172/12/1487    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gelperina, S.
Right arrow Articles by Heifets, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gelperina, S.
Right arrow Articles by Heifets, L.
American Journal of Respiratory and Critical Care Medicine Vol 172. pp. 1487-1490, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.200504-613PP

Pulmonary Perspective

The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis

Svetlana Gelperina, Kevin Kisich, Michael D. Iseman and Leonid Heifets

Research Center for Molecular Diagnostics and Therapy, Moscow, Russian Federation; and National Jewish Medical and Research Center, Denver, Colorado

Correspondence and requests for reprints should be addressed to Leonid Heifets, M.D., Ph.D., National Jewish, 1400 Jackson Street, Denver, CO 80206. E-mail: heifetsl{at}njc.org

ABSTRACT

Nanoparticle-based drug delivery systems have considerable potential for treatment of tuberculosis (TB). The important technological advantages of nanoparticles used as drug carriers are high stability, high carrier capacity, feasibility of incorporation of both hydrophilic and hydrophobic substances, and feasibility of variable routes of administration, including oral application and inhalation. Nanoparticles can also be designed to allow controlled (sustained) drug release from the matrix. These properties of nanoparticles enable improvement of drug bioavailability and reduction of the dosing frequency, and may resolve the problem of nonadherence to prescribed therapy, which is one of the major obstacles in the control of TB epidemics. This article highlights some of the issues of nanotechnology relevant to the anti-TB drugs.

Key Words: antituberculosis drugs • nanoparticles • tuberculosis therapy




This article has been cited by other articles:


Home page
 J Mol Cell BiolHome page
C. Li, H. Liu, Y. Sun, H. Wang, F. Guo, S. Rao, J. Deng, Y. Zhang, Y. Miao, C. Guo, et al.
PAMAM Nanoparticles Promote Acute Lung Injury by Inducing Autophagic Cell Death through the Akt-TSC2-mTOR Signaling Pathway
J Mol Cell Biol, July 2, 2009; (2009) mjp002v2.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. E. M. de Steenwinkel, W. van Vianen, M. T. ten Kate, H. A. Verbrugh, M. A. van Agtmael, R. M. Schiffelers, and I. A. J. M. Bakker-Woudenberg
Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice
J. Antimicrob. Chemother., November 1, 2007; 60(5): 1064 - 1073.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2005 American Thoracic Society 		  Red Transition